Spring Bank Pharmaceuticals is a clinical stage drug discovery company. Based on a proprietary platform technology, the firm is developing a pipeline of products representing a new class of pharmaceuticals called small molecule nucleic acid hybrids SMNH, with a wide range of applications and multi-billion dollar market potential. These rationally designed molecules combine the selectivity of naturally occurring nucleotides, with the drug like properties of classical pharmaceuticals. These SMNHs have the properties of oral delivery, good pharmacokinetics, low side effects and ease of manufacture. The firm's most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C, works by up-regulating the host immune response in the presence of viral infection. Clinical studies for SB 9200 began in early 2013. The firm has a robust pre-clinical pipeline behind SB 9200 with programs in Respiratory Syncytial Virus (RSV), a Broad Spectrum Antiviral and an earlier stage research program for COPD.
